Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 4, 2018 in Breast cancer | 0 comments

In a nutshell

This study wanted to find out which treatment is better for breast cancer, chemotherapy plus trastuzumab (Herceptin) and surgery, or pertuzumab (Perjeta), and chemotherapy plus trastuzumab (Herceptin) and surgery. The study found that adding pertuzumab to the standard treatment worked better to completely remove all signs of cancer compared to the standard treatment alone.

Some background

There are many options for treatment of breast cancer. Some breast cancers can have a mutation in a gene called HER2. Because of this, doctors can use medicine which targets this gene. A common medicine used is called trastuzumab (Herceptin). Other common treatments include chemotherapy and surgery to remove the tumor, which is the standard treatment. Pertuzumab is another anti-cancer medicine. It is thought that adding pertuzumab to standard treatment for breast cancer will result in better outcomes. This has been shown in a number of clinical trials. However, it has not been shown to work in real-world applications outside of clinical trials.

Methods & findings

This study consisted of 300 patients. All the patients had been diagnosed with breast cancer. In total. 192 patients received the standard treatment. The remaining 108 patients had pertuzumab added to their standard treatment.

In the patients who received standard treatment, it was found that 30.2% had no cancer cells left in the body after treatment. In those who received standard treatment plus pertuzumab 52.8% had no cancer cells left in the body after treatment.

The bottom line

This study found that adding pertuzumab to standard treatment for HER2 positive breast cancer resulted in higher rates of complete response, where no cancer cells remain in the body.

The fine print

This study confirms findings that are already known.

What’s next?

Talk to your oncologist about your treatment plan.

Published By :

Breast Cancer Research and Treatment

Date :

Oct 15, 2018

Original Title :

Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.

click here to get personalized updates